Investment analysts at Piper Jaffray lifted their target price on shares of Affymax (NASDAQ: AFFY) from $26.00 to $36.00 in a note issued to investors on Thursday. The firm currently has an “overweight” rating on the stock.

Affymax opened at 26.12 on Thursday. Affymax has a 1-year low of $4.31 and a 1-year high of $26.85. The company’s market cap is $945.3 million.

Affymax last released its earnings data on Wednesday, August 8th. The company reported ($0.89) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.67) by $0.22. Affymax’s revenue was down 80.3% compared to the same quarter last year. Analysts expect that Affymax will post $-1.53 EPS for the current fiscal year.

AFFY has been the subject of a number of other recent research reports. Analysts at Lazard Capital raised their price target on shares of Affymax from $20.00 to $28.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Robert W. Baird raised their price target on shares of Affymax from $20.00 to $25.00 in a research note to investors on Thursday, September 20th. They now have an “outperform” rating on the stock. Finally, analysts at Robert W. Baird reiterated an “outperform” rating on shares of Affymax in a research note to investors on Thursday, August 9th. They now have a $20.00 price target on the stock.

Affymax, Inc. is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions.